Clinical Trial Update: ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ANKTIVA plus BCG versus BCG monotherapy in high-grade non-muscle invasive bladder cancer (BCG-naïve or BCG-exposed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Anktiva (N-803)
• BCG (Bacillus Calmette-Guérin)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: NMIBC | Phase 3 | Status: NOT_YET_RECRUITING